Multi-Institutional Trial of Accelerated Hypofractionated Intensity-Modulated Radiation Therapy for Early-Stage Oropharyngeal Cancer (RTOG 00-22)

详细信息    查看全文

• 作者：Avraham Eisbruch ; Jonathan Harris ; Adam S. Garden ; Clifford K.S. Chao ; William Straube ; Paul M. Harari ; Giuseppe Sanguineti ; Christopher U. Jones ; Walter R. Bosch ; K. Kian Ang
• 刊名：International Journal of Radiation Oncology*Biology*Physics
• 出版年：2010
• 出版时间：April 2010
• 年：2010
• 卷：76
• 期：5
• 页码：1333-1338
• 全文大小：161 K

文摘

Purpose

To assess the results of a multi-institutional study of intensity-modulated radiation therapy (IMRT) for early oropharyngeal cancer.

Patients and Methods

Patients with oropharyngeal carcinoma Stage T1–2, N0–1, M0 requiring treatment of the bilateral neck were eligible. Chemotherapy was not permitted. Prescribed planning target volumes (PTVs) doses to primary tumor and involved nodes was 66 Gy at 2.2 Gy/fraction over 6 weeks. Subclinical PTVs received simultaneously 54–60 Gy at 1.8–2.0 Gy/fraction. Participating institutions were preapproved for IMRT, and quality assurance review was performed by the Image-Guided Therapy Center.

Results

69 patients were accrued from 14 institutions. At median follow-up for surviving patients (2.8 years), the 2-year estimated local-regional failure (LRF) rate was 9 % . 2/4 patients (50 % ) with major underdose deviations had LRF compared with 3/49 (6 % ) without such deviations (p = 0.04). All cases of LRF, metastasis, or second primary cancer occurred among patients who were current/former smokers, and none among patients who never smoked. Maximal late toxicities Grade ≥2 were skin 12 % , mucosa 24 % , salivary 67 % , esophagus 19 % , osteoradionecrosis 6 % . Longer follow-up revealed reduced late toxicity in all categories. Xerostomia Grade ≥2 was observed in 55 % of patients at 6 months but reduced to 25 % and 16 % at 12 and 24 months, respectively. In contrast, salivary output did not recover over time.

Conclusions

Moderately accelerated hypofractionatd IMRT without chemotherapy for early oropharyngeal cancer is feasible, achieving high tumor control rates and reduced salivary toxicity compared with similar patients in previous Radiation Therapy Oncology Group studies. Major target underdose deviations were associated with higher LRF rate.